

PROGRAM <i>Indication</i>	CLASS	ROUTE	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	MILESTONES
<b>Vuolenatide</b> <i>Short Bowel Syndrome</i>	Long-Acting GLP-1	Injectable					Phase 3 initiation → as early as <b>4Q 2022</b>
<b>Larazotide</b> <i>MIS-C*</i>	Tight Junction Regulator	Oral; Gut Restricted					Phase 2a topline data → <b>2H 2022</b>
<b>NM-136</b> <i>Targeted Obesity Disorders</i>	Anti-GIP hu-mAb	Injectable					IND-enabling underway
<b>NM-102</b> <i>Orphan Indication TBD</i>	Tight Junction Microbiome Modulator	Oral					IND-enabling underway
<b>NM-003</b> <i>Orphan Indication TBD</i>	Long-Acting GLP-2	Injectable					IND-enabling underway

**NOTE:** All programs are New Chemical Entities.

**NOTE:** All programs are globally licensed.

\*MIS-C = multisystem inflammatory syndrome in children; clinical trial in collaboration with European Biomedical Research Institute of Salerno (EBRIS)

GLP-1 = glucagon-like peptide-1; GLP-2 = glucagon-like peptide-2; GIP = glucose-dependent insulintropic polypeptide; hu-mAb = humanized monoclonal antibody